Compare Amylx Pharmaceuticals Inc (AMLX) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Open Text Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Open Text Corporation trades at $23.01 (market cap $5.56B). The key difference: Open Text Corporation is far larger — about 2.8× Amylx Pharmaceuticals Inc's market cap, and Open Text Corporation pays a 4.78% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OTEX | |
|---|---|---|
Market Cap | $1.98B | $5.56B |
Sector | Health | Technology |
52-Week High | $18.70 | $39.69 |
52-Week Low | $7.64 | $20.01 |
Enterprise Value | $1.70B | $10.72B |
Dividend Yield | — | 4.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
OTEX trades at $23.01, up 0.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.75 implying 29% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.994 exceeding expectations, and maintains robust profitability with a 73.06% gross margin. Recent developments include a $105 million investment in European AI and cloud expansion and the divestiture of non-core assets.
The outlook is positive given undervalued metrics like a P/E of 11.17 and EV/EBITDA of 6.7, alongside strategic focus on AI and cloud growth. Risks include execution challenges in integrating new investments and competitive pressures in the tech sector. Investor sentiment is cautiously optimistic, supported by analyst upgrades and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
